These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31160277)

  • 1. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer.
    Maeda S; Murakami K; Inoue A; Yonezawa T; Matsuki N
    Cancer Immunol Res; 2019 Jul; 7(7):1175-1187. PubMed ID: 31160277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer.
    Maeda S; Motegi T; Iio A; Kaji K; Goto-Koshino Y; Eto S; Ikeda N; Nakagawa T; Nishimura R; Yonezawa T; Momoi Y
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foxp3
    Maeda S; Nakazawa M; Uchida M; Yoshitake R; Nakagawa T; Nishimura R; Miyamoto R; Bonkobara M; Yonezawa T; Momoi Y
    Vet Pathol; 2020 Jul; 57(4):497-506. PubMed ID: 32347186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
    Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
    J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumors establish resistance to immunotherapy by regulating T
    Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CCL2-CCR4 axis promotes Regulatory T cell trafficking to canine glioma tissues.
    Panek WK; Toedebusch RG; Mclaughlin BE; Dickinson PJ; Van Dyke JE; Woolard KD; Berens ME; Lesniak MS; Sturges BK; Vernau KM; Li C; Miska J; Toedebusch CM
    J Neurooncol; 2024 Sep; 169(3):647-658. PubMed ID: 39046599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
    Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
    J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
    Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis.
    Hagemann UB; Gunnarsson L; Géraudie S; Scheffler U; Griep RA; Reiersen H; Duncan AR; Kiprijanov SM
    PLoS One; 2014; 9(7):e103776. PubMed ID: 25080123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-CCR4 mAb and regulatory T cells].
    Kurose K; Ohue Y; Oka M
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.
    Kurose K; Ohue Y; Wada H; Iida S; Ishida T; Kojima T; Doi T; Suzuki S; Isobe M; Funakoshi T; Kakimi K; Nishikawa H; Udono H; Oka M; Ueda R; Nakayama E
    Clin Cancer Res; 2015 Oct; 21(19):4327-36. PubMed ID: 26429981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXP3/HAT1 Axis Controls Treg Infiltration in the Tumor Microenvironment by Inducing CCR4 Expression in Breast Cancer.
    Sarkar T; Dhar S; Chakraborty D; Pati S; Bose S; Panda AK; Basak U; Chakraborty S; Mukherjee S; Guin A; Jana K; Sarkar DK; Sa G
    Front Immunol; 2022; 13():740588. PubMed ID: 35222362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
    Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
    Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.
    Watanabe M; Kanao K; Suzuki S; Muramatsu H; Morinaga S; Kajikawa K; Kobayashi I; Nishikawa G; Kato Y; Zennami K; Nakamura K; Tsuzuki T; Yoshikawa K; Ueda R; Sumitomo M
    Prostate; 2019 Oct; 79(14):1658-1665. PubMed ID: 31390096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.
    Olkhanud PB; Baatar D; Bodogai M; Hakim F; Gress R; Anderson RL; Deng J; Xu M; Briest S; Biragyn A
    Cancer Res; 2009 Jul; 69(14):5996-6004. PubMed ID: 19567680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
    Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
    Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
    Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
    J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Application of Anti-CCR4 Monoclonal Antibody.
    Ueda R
    Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma.
    Watanabe Y; Katou F; Ohtani H; Nakayama T; Yoshie O; Hashimoto K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):744-52. PubMed ID: 20303300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
    Remer M; Al-Shamkhani A; Glennie M; Johnson P
    Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.